Metabolic dysfunction-associated steatotic liver disease-associated fibrosis and cardiac dysfunction in patients with type 2 diabetes

doi:10.4330/wjc.v16.i10.580

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2064)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-7) series.

Item

Count

PDF

HTML

1159

Figures (1-1)

146

Tables (1-7)

194

Sum=1544

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

109

Download

226

Sum=335

Publishing Process of This Article

Item

Count

Browse

Download

Sum=127

Oct 26, 2024 (publication date) through Feb 27, 2025

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Cardiol. Oct 26, 2024; 16(10): 580-594
Published online Oct 26, 2024. doi: 10.4330/wjc.v16.i10.580

Table 2 Laboratory parameters in the study population according to the liver fibrosis category

Parameter	Group 1 (advanced fibrosis), n = 84	Group 2 (indeterminate risk of fibrosis), n = 164	Group 3 (without fibrosis), n = 19	P value
Uric acid (mg/dL)	6.13 ± 1.44	5.86 ± 1.48	5.29 (3.59-8.17)	0.0484
Albumin (g/dL)	4.59 ± 0.22^a	4.68 ± 0.23^a	4.70 ± 0.28	0.0118
ALAT (U/L)	17.22 (2.32-80.94)	18.02 (4.18-92.79)	25.36 ± 12.56	0.0921
ASAT (U/L)	22.54 (11.48-130.85)^b	19.91 (9.75-49.95)^b	19.30 (13.16-39.16)	0.0034
Direct bilirubin (mg/dL)	0.21 (0.07-0.59)^a	0.20 (0.07-0.90)	0.17 ± 0.06^a	0.0335
GGT (U/L)	32.78 (4.97-338.18)^a	27.51 (4.02-313.66)^a	27.13 (9.17-173.63)	0.0360
Total cholesterol (mg/dL)	147.20 (91.38-279.48)	155.45 (96.75-376.17)	175.16 ± 51.20	0.1347
HDL cholesterol (mg/dL)	43.98 (27.86-65.09)	43.75 (22.48-75.75)	48.04 ± 11.77	0.3977
LDL cholesterol (mg/dL)	73.71 (36.57-186.09)	84.73 (31.2-270.6)	104.01 ± 39.94	0.0488
Triglycerides (mg/dL)	156.02 (70.06-573.36)^a	155.36 (62.37-609.08)^a	117.83 (68.15-382.84)^a	0.0305
Blood glucose (mg/dL)	137.59 (92.09-261.68)	136.58 (87.34-326.2)	142.75 ± 18.60	0.7290
HbA1c (%)	6.80 (4.6-10.01)	6.80 (5.7-10.20)	7.02 ± 0.72	0.5780
C-peptide (ng/mL)	3.68 (0.72-10.5)^a^,^b	3.00 (0.28-8.83)^a	2.62 ± 1.43^b	0.0039
HOMA-IR	3.04 (0.66-8.4)^a	2.61 (0.45-7.52)	2.23 ± 1.21^a	0.0067
eGFR (mL/min/1.73m²)	82.53 (26.70-117.25)^b^,^c	91.38 (40.36-114.59)^a^,^b	97.17 ± 14.60^a^,^c	< 0.0001
Haptoglobin (g/L)	1.59 ± 0.57	1.73 ± 0.61	1.73 ± 0.63	0.1997
Ferritin (ng/mL)	112.00 (8.79-781.00)	92.30 (6.41-811.00)	53.90 (9.72-543.0)	0.6226
SHBP (nmol/L)	37.41 ± 15.12	32.80 (7.62-118.00)	35.38 ± 15.68	0.3811

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

For triglycerides: Group 1 vs group 2, and group 2 vs group 3. Data are presented as mean ± SD or median (min-max). ASAT: Aspartate aminotransferase; ALAT: Alanine aminotransferase; GGT: Gamma glutamyl transpeptidase; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; eGFR: Estimated glomerular filtration rate; HOMA-IR: Homeostatic Model Assessment for Insulin Resistance; SHBP: Sex-hormone binding protein.

Citation: Cernea S, Onișor D, Roiban AL, Benedek T, Rat N. Metabolic dysfunction-associated steatotic liver disease-associated fibrosis and cardiac dysfunction in patients with type 2 diabetes. World J Cardiol 2024; 16(10): 580-594
URL: https://www.wjgnet.com/1949-8462/full/v16/i10/580.htm
DOI: https://dx.doi.org/10.4330/wjc.v16.i10.580